Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.

Abstract: The invention concerns novel nucleic acid and amino acid sequences which are homologs of the PI3K-regulatory subunits. The invention also concerns pharmaceutical compositions containing these sequences as well as methods of detection using the sequences.

Abstract: A molecule is targeted to a leukemia cell by first contacting the cell with a retinoid in an amount effective to increase the expression of a marker in the cell, and the contacting the cell with an agent that specifically binds the marker. For directing a molecule to an acute promyelocytic leukemia cell, the cell is contacted with all-trans retinoic acid to induce or increase expression of CD52 on the cell. The cell is then contacted with a molecule, such as an anti-CD52 antibody, that specifically binds the CD52 expressed on the cell.

Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

Abstract: Methods are provided of diagnosing, treating and testing a subject's susceptibility for schizophrenia, based on investigation of the Notch 4 gene or gene(s) associated therewith. Agents which modify the function of the Notch 4 gene are described used in the treatment of schizophrenia.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cellular proliferation disorders, including, but not limited to, breast cancer, ovarian cancer, lung cancer, and colon cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorders disorder or modulating cellular proliferation. The invention also provides a method for modulating cellular proliferation, e.g., modulating cellular proliferation in a subject. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 25943 polypeptide activity or aberrant 25943 nucleic acid expression.

Abstract: Dendritic cell (DC) genes and polypeptide and their function in the identification of compounds which are (ant)agonists; and (ant)agonists to DC polypeptides.

Abstract: The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as “TNFR-5” or “TR5,” and now referred to hereinafter as “TRAIL receptor without intracellular domain” or “TRID.” TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.

Abstract: Compositions and methods are provided for the treatment of conditions associated with cell proliferation, cell differentiation and cell survival. In particular, the dual-specificity phosphatase DSP-9, and polypeptide variants thereof that stimulate dephosphorylation of DSP-9 substrates, are provided. The polypeptides may be used, for example, to identify antibodies and other agents that inhibit DSP-9 activity. The polypeptides and agents may be used to modulate cell proliferation, differentiation and survival.

Abstract: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a tPA inhibitor, and the use thereof for treating bleeding episodes.

Abstract: The invention provides isolated nucleic acids molecules, designated 32132 nucleic acid molecules, which encode novel fucosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32132 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32132 gene has been introduced or disrupted. The invention still further provides isolated 32132 proteins, fusion proteins, antigenic peptides and anti-32132 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: Isolated nucleic acids molecules, designated 48149 nucleic acid molecules, which encode human Aminopeptidase N, are disclosed. The invention provides methods of modulating 48149 activity, which is associated with the formation of atherosclerotic lesions in blood vessels. The invention further provides methods of treating, preventing and diagnosing cardiovascular disorders such as atherosclerosis, as well as disorders associated with the metabolism of lipids, for example, in the liver.

Abstract: The invention provides human fatty acid beta-oxidation enzymes (HUFA) and polynucleotides which identify and encode HUFA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUFA.

Abstract: The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease.

Abstract: The present invention provides methods and compositions for the diagnosis and treatment of cellular proliferation disorders, e.g., cancer, including, but not limited to colon, ovarian, and lung cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorder. The invention also provides methods for identifying a compound capable of modulating a cellular proliferation disorder. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 86604 polypeptide activity or aberrant 86604 nucleic acid expression.

Abstract: The present invention relates to uses of non-thiol ACE inhibitors, angiotensin II antagonists, angiotensin II receptor antagonists, endonuclease inhibitors, and caspase-inhibitors to treat pulmonary fibrosis and/or inhibit pulmonary epithelial cell apoptosis, including pulmonary fibrosis associated with amiodarone product toxicity.

Abstract: The invention provides isolated nucleic acids molecules, designated 7118 nucleic acid molecules, which encode novel arginine N-methyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 7118 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 7118 gene has been introduced or disrupted. The invention still further provides isolated 7118 proteins, fusion proteins, antigenic peptides and anti-7118 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Reagents which regulate human transketolase-like enzyme and reagents which bind to human transketolase-like enzyme gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, anemia, and end-stage renal disease, including sensory periphery neuropathy associated with uremia.

Abstract: Manipulation of the EphB6 receptor and its active Eph partners allow for regulation of T cell responses, including TCR signalling, T cell proliferation, and induction of T cell death. Methods of modulating EphB6 are described as well as various therapeutic applications.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cellular proliferation disorders, including, but not limited to, breast cancer, ovarian cancer, lung cancer, and colon cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorders disorder or modulating cellular proliferation. The invention also provides a method for modulating cellular proliferation, e.g., modulating cellular proliferation in a subject. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 54394 polypeptide activity or aberrant 54394 nucleic acid expression.

Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue.

Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.

Abstract: An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to the sequence SEQ ID NOS:4 or 6, polynucleotides encoding these peptides, and antibodies to the polypeptides are useful in treating metabolic disorders or disorders associated with changes in adipose tissue physiological function or mass.

Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cellular proliferative disorders, including, but not limited to, lung, breast, ovary, and colon tumors. The invention further provides methods for identifying a compound capable of treating a cellular proliferative disorder or modulating tumorigenesis. The invention also provides a method for modulating tumorigenesis, e.g., modulating tumorigenesis in a subject. In addition, the invention provides a method for treating a subject having a cellular proliferative disorder characterized by aberrant 32222 polypeptide activity or aberrant 32222 nucleic acid expression.

Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.

Abstract: This invention provides methods and compositions for the detection, diagnosis and treatment of amyloid-associated diseases, in particular, diseases comprising deposition of amyloid assemblies, fibrils, filaments, tangles, or plaques. A preferred composition comprises monoclonal antibodies that specifically bind amyloid proteins, peptides or fragments and change the conformation.

Abstract: The present invention provides methods and compositions for the diagnosis and treatment of cellular proliferation disorders, e.g., cancer, including, but not limited to colon, breast, and lung cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorder. The invention also provides methods for identifying a compound capable of modulating a cellular proliferation disorder. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 20750 polypeptide activity or aberrant 20750 nucleic acid expression.

Abstract: The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit.

Abstract: The invention relates to anti-procalcitonin antibodies, their preparation and use, in particular in therapy and diagnostics. The antibodies comprise binding to procalcitonin but not to free calcitonin, free katacalcin and free N-procalcitonin.

Abstract: A human inhibitor of apoptosis polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of degenerative diseases, rheumatoid arthritis, septic shock, as an antiviral defense mechanism and to prevent the death of cells during trauma and strokes. Antagonists against such polypeptides and their use as a therapeutic to promote cell development, kill viral infections, promote tissue differentiation and development and maintain tissue homeostasis are also disclosed (tumors). Diagnostic methods for detecting mutations in the nucleic acid sequence encoding hIAP-1 protein are also disclosed.

Abstract: A method of treating a patient suffering from a pathological condition characterized by expression of FAP&agr;, the method comprising administering to the patient a therapeutically effective amount of an antibody which specifically binds to FAP&agr;. A pharmaceutical composition comprising an antibody which specifically binds to FAP&agr;, wherein the antibody is radiolabeled with 131I, 90Y, 186Re, or 188Re, and wherein the antibody has specific activity of from about 0.5 to about 15 mCi/mg, is also provided.

Abstract: Reagents which regulate human mast cell protease 6-like enzyme activity and reagents which bind to human mast cell protease 6-like enzyme gene products can he used to regulate human mast cell protease 6 like enzyme activity. Such regulation is particularly useful for treating metastasis of malignant cells, tumor angiogenesis, inflammation including asthma, atherosclerosis, neurodegenerative diseases, and pathogenic infections.

Abstract: Methods of identifying anti-cancer agents are provided based on ligand binding or enzymatic activity of TIP49 family members. The assays may include the measurement of ATPase and/or helicase activity. Also provided are anti-cancer agents identified by the screening methods of the invention, as well as the use of the agent for the prophylaxis or treatment of cancer. A complex of a TIP49 family member with various proteins that regulate transcription is also provided.

Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.

Abstract: The present invention relates to methods for the diagnosis and treatment of a urological disorder or urological disorders. Specifically, the present invention identifies the differential expression of 313, 333, 5464, 18817 or 33524 genes in tissues relating to urological disorder, relative to their expression in normal, or non-urological disorder disease states, and/or in response to manipulations relevant to a urological disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urological diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a urological disorder or urological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of urological disorders.

Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

Abstract: The present invention provides a novel protein tyrosine kinase (HPTYK) and polynucleotides which identify and encode HPTYK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPTYK and a method for producing HPTYK. The invention also provides pharmaceutical compositions containing HPTYK or antagonists to HPTYK, and for the use of these compositions in the treatment of diseases associated with the expression of HPTYK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPTYK for the treatment of diseases associated with the expression of HPTYK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HPTYK or antibodies which specifically bind to HPTYK.

Abstract: The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions #involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.

Abstract: A remedy for interstitial pneumonia, comprising at least one, or two or more kinds of an interleukin 18 inhibitor and/or an interleukin 2 inhibitor as an active ingredient.

Abstract: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.

Abstract: The invention provides isolated nucleic acids molecules, designated 21132 nucleic acid molecules, which encode novel GPCR family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21132 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21132 gene has been introduced or disrupted. The invention still further provides isolated 21132 proteins, fusion proteins, antigenic peptides and anti-21132 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention is directed to pharmaceutical compositions comprising a telomerase reverse transcriptase polypeptide or a polypeptide homologous to a telomerase reverse transcriptase. The present invention is also directed to pharmaceutical compositions comprising a polynucleotide encoding either of the aforesaid polypeptides. The present invention is further directed to methods for eliciting an immune response to telomerase reverse transcriptase in a subject.

Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.

Abstract: The present invention relates to a method of modulating resistance to apoptosis in a patient. The treatment consists of administering to a patient a therapeutically effective amount of an enhancing agent which selectively inhibits or stimulates the function of PAX-2. The enhancing agent of the present invention allows to increase or to reduce resistance to apoptosis depending of targeted cells.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders, including, but not limited to, inflammatory pain, chronic pain and/or neuropathic pain. The invention further provides methods for identifying a compound capable of treating a pain disorder or modulating pain and/or inflammation. The invention further provides a method for modulating pain and/or inflammation in a subject. In addition, the invention provides a method for treating a subject having a pain disorder characterized by aberrant 2047 polypeptide activity or aberrant 2047 nucleic acid expression.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders, including, but not limited to, inflammatory pain, chronic pain and/or neuropathic pain. The invention further provides methods for identifying a compound capable of treating a pain disorder or modulating pain and/or inflammation response. The invention further provides a method for modulating pain and/or inflammation in a subject. In addition, the invention provides a method for treating a subject having a pain disorder characterized by aberrant 46566 polypeptide activity or aberrant 46566 nucleic acid expression.

Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g., blood diorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 2777 polypeptide activity or aberrant 2777 nucleic acid expression.

Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells, such as renal cell carcinoma. Such gene amplification is expected to be associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, such as renal cell carcinoma, and may act as predictors of the prognosis of tumor treatment. The present invention is directed to novel methods of diagnosing and treating tumor, such as renal cell carcinoma.

Abstract: A pharmaceutical composition for the treatment or prophylaxis of disorders is described in which the overproduction of s-CD23 is implicated. This composition comprises an inhibitor for the formation of human soluble CD23, which inhibitor decreases or blocks selectively the activity of the metalloprotease ADAM9, which otherwise mediates the shedding of s-CD23 in human B cells and monocytes/macrophages. Also described is a pharmaceutical composition wherein the inhibitor for the formation of human soluble CD23 is a monoclonal or polyclonal antibody directed against the metalloprotease ADAM9. Such a pharmaceutical composition may be used in a method for selectively inhibiting the formation of s-CD23. It is a suitable medicament against inflammatory disorders, autoimmune diseases and allergy.